Company file · Korea · Pharma

Yuhan

We look for people who turn external science into reusable internal capability and translate evidence across research, development, clinical, quality and business boundaries.

Talent patterns 2Business changes confirmed 5Roles visible in hiring 13Reviewed 2026-09-24

Talent patterns

See which experience may become scarce first.

Talent pattern 1Early watch

The scarcer experience may be turning a good external technology into capability the company can reuse.

Capability · Capability Internalization

The capability to convert externally sourced science into internal research methods, evaluation standards and development know-how that the company can reuse across assets.

Finding or licensing a strong technology is different from making the organization itself able to use that knowledge repeatedly.

Why now

Yuhan combines continued investment in internal R&D with open innovation, while Yuhan USA scouts assets and partnerships and the central research institute maintains substantial internal discovery and development infrastructure.

Core capability

External Science Absorption
Internal Learning
Owned Capability
Reusable Method

Experience that strengthens it

Discovery Research
Research Science
Translational Research
Tech Transfer
Business Development

Who to look at first: Discovery / Research Science / Translational / Scientific BD depth plus technology absorption and internal-capability build experience
What to check in the interview: Ask for a concrete case where external technology became an internal assay, candidate-selection rule, development method or reusable know-how.
Build internally: Give External Innovation and BD roles explicit responsibility for technology absorption and handoff into internal R&D.; Which companies and teams to search for these people is part of the candidate market analysis →

Signals that strengthen this view

External technologies are repeatedly converted into internal assays, evaluation methods or development standards
Science scouted through Yuhan USA becomes reusable capability inside the research organization and pipeline
An internalized method created for one asset is reused across additional programs

Conditions that lower this view

Lower this view if external technologies mostly remain partner-executed and do not repeatedly become internal research methods or decision capability.

View evidence7

Roles & capabilities

Discovery ResearchPersistent

Research SciencePersistent

Translational ResearchObserved again

Tech TransferObserved again

Business changes

Yuhan repeatedly scales assets through global technology-transfer partnershipsSource ↗

Yuhan links open innovation to pipeline value, global clinical development and market entrySource ↗

Yuhan USA operates as a global asset-scouting and partnering nodeSource ↗

Talent pattern 2Early watch

The valuable experience may be making the next function able to use your output—not simply working with many functions.

Capability · Cross-Node Translation

The capability to turn science, evidence and requirements from one function into criteria, language and formats the next function can use for real decisions and execution.

Working with many functions is different from defining a handoff that makes the next function immediately able to decide and execute.

Why now

Yuhan’s R&D roadmap explicitly connects open innovation to pipeline-value expansion, global clinical development, productization and global market entry as one execution chain.

Core capability

Evidence Translation
Decision Standard
Cross-functional Handoff
Execution Readiness

Experience that strengthens it

Translational Research
Clinical Operations
CMC
Quality
Manufacturing
Business Development

Who to look at first: Translational / Clinical / CMC / Quality / Manufacturing / BD depth plus cross-functional decision-translation experience
What to check in the interview: Ask what was handed off, which acceptance criteria were defined and what decision the receiving function executed.
Build internally: Define translation ownership at key Discovery→Development→Clinical→CMC/Quality→Business boundaries.; Which companies and teams to search for these people is part of the candidate market analysis →

Signals that strengthen this view

Formal handoff standards strengthen across external science, Discovery, Clinical, CMC and Quality
New modalities materially change existing evaluation, development or quality standards
Explicit translation ownership grows across global BD, R&D, development/business and manufacturing-quality nodes

Conditions that lower this view

Lower this view if cross-functional work remains generic coordination and evidence translation or handoff standards do not become a repeated capability.

View evidence7

Roles & capabilities

Translational ResearchObserved again

Business DevelopmentObserved again

Manufacturing

Quality Assurance

Business changes

Yuhan repeatedly scales assets through global technology-transfer partnershipsSource ↗

Yuhan links open innovation to pipeline value, global clinical development and market entrySource ↗

Yuhan USA operates as a global asset-scouting and partnering nodeSource ↗

CURRENT EVIDENCE

Start with what is currently observed.

Date being confirmed
PartnershipYuhan repeatedly scales assets through global technology-transfer partnerships
Multiple global licensing relationships show repeated use of external counterparties to amplify development and commercialization reach.
Source: ↗
Date being confirmed
Pipeline changeYuhan links open innovation to pipeline value, global clinical development and market entry
The formal R&D roadmap connects external inputs to internal pipeline development and global execution.
Source: ↗
Date being confirmed
Global expansionYuhan USA operates as a global asset-scouting and partnering node
The U.S. subsidiary evaluates in-licensing and investment opportunities while supporting out-licensing and strategic collaborations.
Source: ↗
Date being confirmed
PartnershipYuhan institutionalizes research collaboration, tech transfer and licensing-in/out
External institutions are used as recurring sources of science, knowledge and development opportunities rather than as one-time suppliers.
Source: ↗
2026-09-15
PartnershipSource: 단일판매·공급계약 체결 ↗

Current roles & capabilities

Discovery Research Persistent
Research Science Persistent
Translational Research Observed again
Tech Transfer Observed again
Alliance Management Observed again
Global Business Observed again
Business Development Observed again
Manufacturing Currently observed
Quality Assurance Currently observed
CMC Currently observed
Clinical Operations Currently observed
Validation Currently observed
Process Development Currently observed

Repeatedly observed: confirmed at several points in time · Observed: confirmed recently

Banseog analysisYuhan repeatedly converts external science into owned capability and routes it across research, development, quality and global partner nodes

CURRENT TALENT MARKET

Then see the talent market moving around it.

Who else is looking at the same talent?

Talent competitorProcess DevelopmentBanseog analysis
Talent competitorClinical OperationsBanseog analysis

Abbreviations on this page

CMC: Chemistry, manufacturing and controls
BD: Business development

Candidate market analysis for Yuhan

We analyse the candidate field, adjacent talent markets and hiring sequence for this shift. The detailed candidate field is shared only with the commissioning company.

Request an analysis →

To read this shift as a management decision, see Banseog Strategy →